Answer
Starting siponimod fumaric acid after alemtuzumab is not recommended because of the characteristics and duration of alemtuzumab’s immunosuppressive effects and the potential for additive immune effects.
Sources for this answer
- Mayzent 0.25 mg, 1 mg & 2 mg film-coated tabletsNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 8Document updated
Sources checked